INVA Q3 2024 Earnings — Innoviva, Inc. Revenue & Financial Results | Market Cap Arena

INVAInnoviva, Inc.

$1B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$90M+33.1% YoY

Gross Profit

$80M88.8% margin

Operating Income

$50M55.6% margin

Net Income

$1M1.4% margin

EPS (Diluted)

$0.02

QoQ Revenue Growth

-13.4%

Cash Flow

Operating Cash Flow

$49M

Free Cash Flow

$48M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$563M

Stockholders' Equity

$669M

Cash & Equivalents

$261M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$90M	$67M	+33.1%
Gross Profit	$80M	$57M	+39.6%
Operating Income	$50M	$24M	+104.6%
Net Income	$1M	$82M	-98.5%

Revenue Segments

Royalty

$57M64%

Product

$28M31%

License Revenue

$5M5%